

Running Header: Barriers and facilitators

scleroderma: a Scleroderma

**Barriers and facilitators to physical activity for people with**

**Patient-centered Intervention Network (SPIN) Cohort study**

**Running head:** Barriers and facilitators

Sami Harb, BSc<sup>1,2</sup>; Sandra Peláez, PhD<sup>1,3</sup>; Marie-Eve Carrier, MSc<sup>1</sup>; Linda Kwakkenbos, PhD<sup>4</sup>;

Susan J. Bartlett, PhD<sup>5</sup>; Marie Hudson, MD, MPH<sup>1,5</sup>; Luc Mouthon, MD, PhD<sup>6,7</sup>; Maureen

Sauvé<sup>8</sup>; Joep Welling<sup>9</sup>; Ian Shrier, MD, PhD<sup>1</sup>; Brett D. Thombs, PhD<sup>1,2,5,10-13</sup>; for the

Scleroderma Patient-centered Intervention Network (SPIN) – Physical Activity Enhancement

Patient Advisory Team<sup>13</sup> and SPIN Investigators<sup>14</sup>

<sup>1</sup>Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada;

<sup>2</sup>Department of Psychiatry, McGill University, Montreal, Canada; <sup>3</sup>Research Centre, Centre

Hospitalier Universitaire Sainte-Justine, Montreal, Canada; <sup>4</sup>Behavioural Science Institute,

Clinical Psychology, Radboud University, Nijmegen, the Netherlands; <sup>5</sup>Department of Medicine,

McGill University, Montreal, Canada; <sup>6</sup>Assistance Publique - Hôpitaux de Paris, Université Paris

Descartes, Paris, France; <sup>7</sup>Service de Médecine Interne, Hôpital Cochin, Paris, France;

<sup>8</sup>Scleroderma Canada and Scleroderma Society of Ontario, Hamilton, Canada; <sup>9</sup>Federation of

European Scleroderma Associations, Brussels, Belgium; <sup>10</sup>Department of Epidemiology,

Biostatistics and Occupational Health, McGill University, Montreal, Canada; <sup>11</sup>Department of

Psychology, McGill University, Montreal, Canada; <sup>12</sup>Department of Educational and Counselling

Psychology, McGill University, Montreal, Canada; <sup>13</sup>Biomedical Ethics Unit, McGill University,

Montreal, Canada; <sup>14</sup>Scleroderma Patient-centered Intervention Network (SPIN) – Physical

24 Activity Enhancement Patient Advisory Team members: Lindsay Cronin, Southwestern  
25 Pennsylvania Scleroderma Support Group, Pittsburgh, USA; Catherine Fortuné, Ottawa  
26 Scleroderma Support Group, Ottawa, Canada; Amy Gietzen, Scleroderma Foundation, Danvers,  
27 USA; Geneviève Guillot, Sclérodermie Québec, Longueuil, Canada; Shirley Haslam,  
28 Scleroderma Society of Ontario, Hamilton, Canada; Karen Nielsen, Scleroderma Society of  
29 Ontario, Hamilton, Canada; Michelle Richard, Scleroderma Atlantic, Halifax, Canada; Ken  
30 Rozee, Scleroderma Atlantic, Halifax, Canada; Joep Welling, Federation of European  
31 Scleroderma Associations, Brussels, Belgium; <sup>15</sup>SPIN Investigators: Murray Baron, McGill  
32 University, Montreal, Quebec, Canada; Daniel E. Furst, Division of Rheumatology, Geffen  
33 School of Medicine, University of California, Los Angeles, California, USA; Karen Gottesman,  
34 Scleroderma Foundation, Los Angeles, California, USA; Vanessa Malcarne, San Diego State  
35 University, San Diego, California, USA; Maureen D. Mayes, University of Texas McGovern  
36 School of Medicine, Houston, Texas, USA; Warren R. Nielson, St. Joseph's Health Care,  
37 London, Ontario, Canada; Robert Riggs, Scleroderma Foundation, Danvers, Massachusetts,  
38 USA; Fredrick Wigley, Johns Hopkins University School of Medicine, Baltimore, Maryland,  
39 USA; Shervin Assassi, University of Texas McGovern School of Medicine, Houston, Texas,  
40 USA; Andrea Benedetti, McGill University, Montreal, Quebec, Canada; Isabelle Boutron,  
41 Université Paris Descartes, and Assistance Publique - Hôpitaux de Paris, Paris, France; Ghassan  
42 El-Baalbaki, Université du Québec à Montréal, Montreal, Quebec, Canada; Carolyn Ells, McGill  
43 University, Montreal, Quebec, Canada; Cornelia van den Ende, Sint Maartenskliniek, Nijmegen,  
44 the Netherlands; Kim Fligelstone, Scleroderma & Raynaud's UK, London, UK; Tracy Frech,  
45 University of Utah, Salt Lake City, Utah, USA; Dominique Godard, Association des  
46 Sclérodermiques de France, Sorel-Moussel, France; Daphna Harel, New York University, New

47 York, New York, USA; Monique Hinchcliff, Yale School of Medicine, New Haven,  
48 Connecticut, USA; Sindhu R. Johnson, Toronto Scleroderma Program, Mount Sinai Hospital,  
49 Toronto Western Hospital, and University of Toronto, Toronto, Ontario, Canada; Maggie  
50 Larche, McMaster University, Hamilton, Ontario, Canada; Catarina Leite, University of Minho,  
51 Braga, Portugal; Christelle Nguyen, Université Paris Descartes, and Assistance Publique -  
52 Hôpitaux de Paris, Paris, France; Elisabet Pérez, Asociación Española de Esclerodermia, Madrid,  
53 Spain; Janet Pope, University of Western Ontario, London, Ontario, Canada; François Rannou,  
54 Université Paris Descartes, and Assistance Publique - Hôpitaux de Paris, Paris, France; Tatiana  
55 Sofia Rodriguez Reyna, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,  
56 Mexico City, Mexico; Anne A. Schouffoer, Leiden University Medical Center, Leiden, the  
57 Netherlands; Maria E. Suarez-Almazor, University of Texas MD Anderson Cancer Center,  
58 Houston, Texas, USA; Christian Agard, Centre Hospitalier Universitaire - Hôtel-Dieu de Nantes,  
59 Nantes, France; Nassim Ait Abdallah, Assistance Publique - Hôpitaux de Paris, Hôpital St-Louis,  
60 Paris, France; Alexandra Albert, CHU de Québec - Université Laval, Quebec, Quebec, Canada;  
61 Marc André, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France;  
62 Guylaine Arsenault, Université de Sherbrooke, Sherbrooke, Quebec, Canada; Elana J. Bernstein,  
63 Columbia University, New York, New York, USA; Sabine Berthier, Centre Hospitalier  
64 Universitaire Dijon Bourgogne, Dijon, France; Lyne Bissonnette, Université de Sherbrooke,  
65 Sherbrooke, Quebec, Canada; Gilles Boire, Université de Sherbrooke, Sherbrooke, Quebec,  
66 Canada; Alessandra Bruns, Université de Sherbrooke, Sherbrooke, Quebec, Canada; Patricia  
67 Carreira, Servicio de Reumatología del Hospital 12 de Octubre, Madrid, Spain; Marion  
68 Casadevall, Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Paris, France; Benjamin  
69 Chaigne, Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Paris, France; Pascal Cohen,

70 Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Paris, France; Chase Correia,  
71 Northwestern University, Chicago, Illinois, USA; Pierre Dagenais, Université de Sherbrooke,  
72 Sherbrooke, Quebec, Canada; Christopher Denton, Royal Free London Hospital, London, UK;  
73 Robyn Domsic, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; Sandrine Dubois,  
74 Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France; James  
75 V. Dunne, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia,  
76 Canada; Bertrand Dunogue, Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Paris,  
77 France; Regina Fare, Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain;  
78 Dominique Farge-Bancel, Assistance Publique - Hôpitaux de Paris, Hôpital St-Louis, Paris,  
79 France; Paul R. Fortin, CHU de Québec - Université Laval, Quebec, Quebec, Canada; Anna  
80 Gill, Royal Free London Hospital, London, UK; Jessica Gordon, Hospital for Special Surgery,  
81 New York, New York, USA; Brigitte Granel-Rey, Aix Marseille Université, and Assistance  
82 Publique - Hôpitaux de Marseille, Hôpital Nord, Marseille, France; Genevieve Gyger, Jewish  
83 General Hospital and McGill University, Montreal, Quebec, Canada; Eric Hachulla, Centre  
84 Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France; Pierre-Yves  
85 Hatron, Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France;  
86 Ariane L Herrick, University of Manchester, Salford Royal NHS Foundation Trust, Manchester,  
87 UK; Sabrina Hoa, Centre hospitalier de l'Université de Montréal – CHUM, Montreal, Quebec,  
88 Canada; Alena Ikic, Université Laval, Quebec, Quebec, Canada; Niall Jones, University of  
89 Alberta, Edmonton, Alberta, Canada; Artur Jose de B. Fernandes, Université de Sherbrooke,  
90 Sherbrooke, Quebec, Canada; Suzanne Kafaja, University of California, Los Angeles, California,  
91 USA; Nader Khalidi, McMaster University, Hamilton, Ontario, Canada; Marc Lambert, Centre  
92 Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France; David Launay,

93 Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France; Patrick  
94 Liang, Université de Sherbrooke, Sherbrooke, Quebec, Canada; Hélène Maillard, Centre  
95 Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France; Nancy Maltez,  
96 University of Ottawa, Ottawa, Ontario, Canada; Joanne Manning, Salford Royal NHS  
97 Foundation Trust, Salford, UK; Isabelle Marie, CHU Rouen, Hôpital de Bois-Guillaume, Rouen,  
98 France; Maria Martin, Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain;  
99 Thierry Martin, Les Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg,  
100 France; Ariel Masetto, Université de Sherbrooke, Sherbrooke, Quebec, Canada; François  
101 Maurier, Hôpitaux Privés de Metz, Hôpital Belle-Isle, Metz, France; Arsene Mekinian,  
102 Assistance Publique - Hôpitaux de Paris, Hôpital St-Antoine, Paris, France; Sheila Melchor,  
103 Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain; Mandana Nikpour, St  
104 Vincent's Hospital and University of Melbourne, Melbourne, Victoria, Australia; Louis Olagne,  
105 Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France; Vincent  
106 Poindron, Les Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France;  
107 Susanna Proudman, Royal Adelaide Hospital and University of Adelaide, Adelaide, South  
108 Australia, Australia; Alexis Régent, Assistance Publique - Hôpitaux de Paris, Hôpital Cochin,  
109 Paris, France; Sébastien Rivière, Assistance Publique - Hôpitaux de Paris, Hôpital St-Antoine,  
110 Paris, France; David Robinson, University of Manitoba, Winnipeg, Manitoba, Canada; Esther  
111 Rodriguez, Servicio de Reumatologia del Hospital 12 de Octubre, Madrid, Spain; Sophie Roux,  
112 Université de Sherbrooke, Sherbrooke, Quebec, Canada; Perrine Smets, Centre Hospitalier  
113 Universitaire Gabriel-Montpied, Clermont-Ferrand, France; Vincent Sobanski, Centre  
114 Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille, France; Robert Spiera,  
115 Hospital for Special Surgery, New York, New York, USA; Virginia Steen, Georgetown

University, Washington, DC, USA; Wendy Stevens, St Vincent's Hospital and University of Melbourne, Melbourne, Victoria, Australia; Evelyn Sutton, Dalhousie University, Halifax, Nova Scotia, Canada; Benjamin Terrier, Assistance Publique -Hôpitaux de Paris, Hôpital Cochin, Paris, France; Carter Thorne, Southlake Regional Health Centre, Newmarket, Ontario, Canada; John Varga, Northwestern University, Chicago, Illinois, USA; Pearce Wilcox, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada; Angelica Bourgeault, Jewish General Hospital, Montreal, Quebec, Canada; Mara Cañedo-Ayala, Jewish General Hospital, Montreal, Quebec, Canada; Andrea Carboni-Jiménez, Jewish General Hospital, Montreal, Quebec, Canada; Maria Gagarine, Jewish General Hospital, Montreal, Quebec, Canada; Richard S. Henry, Jewish General Hospital, Montreal, Quebec, Canada; Nora Østbø, Jewish General Hospital, Montreal, Quebec, Canada; Lydia Tao, Jewish General Hospital, Montreal, Quebec, Canada.

**Address for Correspondence:** Dr. Brett D. Thombs, Jewish General Hospital; 4333 Cote Ste Catherine Road; Montréal, Québec, H3T 1E4, Canada; Tel (514) 340-8222 ext. 25112.  
brett.thombs@mcgill.ca

**Financial support:** This research was supported by a Canadian Institutes of Health Research – Strategy for Patient-Oriented Research Grant (PI Shrier) with partner funding from the Scleroderma Society of Ontario. Mr. Harb was supported by a CIHR Canada Graduate Scholarship-Master's award. Dr. Thombs was supported by a Fonds de Recherche du Québec - Santé researcher salary award.

139 **Word count:** 3745

140

**ABSTRACT**

**Objective:** To support physical activity among people with systemic sclerosis (SSc; scleroderma), we sought to determine the (1) prevalence and importance of barriers and (2) likelihood of using possible facilitators.

**Methods:** We invited 1,707 participants from an international SSc cohort to rate the (1) importance of 20 barriers (14 medical; 4 social or personal; 1 lifestyle; 1 environmental); and (2) likelihood of using 91 corresponding barrier-specific and 12 general facilitators.

**Results:** Among 721 respondents, 13 barriers were experienced by  $\geq 25\%$  of participants, including 2 (fatigue, Raynaud's) rated 'important' or 'very important' by  $\geq 50\%$  of participants, 7 (joint stiffness and contractures, shortness of breath, gastrointestinal problems, difficulty grasping, pain, muscle weakness and mobility limitations, low motivation) by 26-50%, and 4 by  $< 26\%$ . Overall, 23 (18 medical-related) of 103 facilitators were rated by  $\geq 75\%$  as 'likely' or 'very likely' to use among those who experienced corresponding barriers; these facilitators focused on adapting exercise (e.g., using controlled, slow movement), taking care of one's body (e.g., stretching), keeping warm (e.g., wearing gloves), and protecting skin (e.g., covering ulcers). Among those who had previously tried the facilitator, all facilitators were rated by  $\geq 50\%$  as 'likely' or 'very likely' to use; among those with the barrier who had not tried the facilitator, only 12 of 103 were rated by  $> 50\%$  as 'likely' or 'very likely'.

**Conclusion:** Medical-related physical activity barriers were common and considered important. Facilitators considered as most likely to be used involved adapting exercise, taking care of one's body, keeping warm, and protecting skin.



## **Significance and Innovations**

- Based on a survey of 721 people with scleroderma, barriers to physical activity most commonly considered important involved compromised hand dexterity or condition (e.g., Raynaud's phenomenon), general symptoms (e.g., fatigue) or localized symptoms (e.g., gastrointestinal problems), and low motivation.
- Barrier-specific physical activity facilitators most likely to be used addressed adapting the exercise type or setting; using health behaviours to take care of the body; and strategies to keep warm and protect the skin.
- Generally, participants who experienced the barrier and had tried the linked facilitator were likely to use it, whereas participants who experienced the barrier and had not tried the linked facilitator were not likely to use it.
- Health care providers can use facilitators identified in this study to adapt physical activity options so that people with scleroderma can overcome barriers to physical activity.

Systemic sclerosis (SSc; scleroderma) is a rare chronic, autoimmune rheumatic disease characterized by abnormal fibrotic processes and excessive collagen production that can affect the skin, musculoskeletal system, and internal organs, including the heart, lungs, and gastrointestinal tract (1, 2). People with SSc experience significantly lower health-related quality of life in comparison to the general population (3). Disease onset typically occurs at around 50 years, and approximately 80% of people with SSc are women (4, 5).

Although regular physical activity is important to enhance health for all people (6, 7), including those with autoimmune rheumatic diseases (8), people with SSc experience a wide range of barriers that may impede engagement. Data from a large international SSc cohort demonstrated that approximately 50% of patients were physically inactive, and patients who were active rarely engaged in activities other than walking (9). That study and other studies on physical activity in SSc (10-12) have not addressed barriers or facilitators to being physically active.

For health care providers to advise SSc patients on how to be physically active, they need to be able to identify possible facilitators, or strategies, to overcome specific barriers faced by individual patients. We previously conducted a nominal group technique study to identify barriers to physical activity, along with potential facilitators, experienced by people with SSc (13). That study included only 41 people, which did not allow conclusions to be drawn about the prevalence of barriers and likelihood that people with SSc would use identified facilitators. The aim of the present study was to obtain information on the prevalence of barriers and perceived utility of facilitators to help tailor physical activity recommendations to the specific needs of people with SSc. Specific objectives were to determine (1) the prevalence and importance of

different barriers experienced in SSc, and (2) likelihood that people with SSc would use different patient-generated barrier-specific and general facilitators to support physical activity.

## **Patients and Methods**

This was a cross-sectional study in which survey results from the Scleroderma Patient-centered Intervention Network (SPIN) Physical Activity Survey were deterministically linked using participant user names (email addresses) to participant sociodemographic, medical, and patient-reported outcome measure data from the ongoing SPIN Cohort.

### ***Participants and Procedures***

We surveyed participants enrolled in the SPIN Cohort. Eligible SPIN Cohort participants must be classified as having SSc according to the 2013 ACR/EULAR criteria (14);  $\geq 18$  years of age; fluent in English, French, or Spanish; and able to respond to questionnaires via the Internet. Eligible individuals are invited by their attending physician or supervised nurse coordinator to participate in the SPIN Cohort, and written informed consent is obtained. The local SPIN physician or supervised nurse coordinator completes a medical data form that is submitted online to initiate participant registration. After completion of online registration, an automated welcoming email is sent to participants with instructions for activating their SPIN account and completing SPIN Cohort measures online. SPIN Cohort participants complete online outcome measures upon enrollment and subsequently every 3 months.

For the present study, in July 2019 we invited active SPIN Cohort participants to complete a survey, separately from their routine cohort assessments. We sent email invitations to all 1,707 SPIN Cohort participants who had active SPIN accounts and who complete assessments in English or French. We sent follow-up emails 2, 4, and 8 weeks later to those who had not completed the survey. In addition, we advertised the survey through an announcement presented

to SPIN Cohort participants when they logged into the SPIN Cohort portal to complete their routine online assessments. To promote participation, we informed participants that one survey respondent would be randomly selected to win a trip to the 2020 SSc World Congress in Prague, Czech Republic. The email invitation and announcements provided a link to the survey on *Qualtrics* (15). In *Qualtrics*, participants entered their SPIN username (email address) in order to access and complete the survey questions. The survey was closed in October 2019. We excluded participants who only partially completed the survey. SPIN Cohort assessment data were obtained from the most recently completed assessments prior to completing the SPIN Physical Activity Survey for participants and prior to the initial survey invitation for non-participants, without time restriction.

The SPIN Cohort was approved by the Research Ethics Committee of the Centre intégré universitaire de santé et de services sociaux du Centre-Ouest-de-l'Île-de-Montréal (#MP-05-2013-150) and by the research ethics committees of each participating centre. The present study was approved as an amendment to the SPIN Cohort by the Research Ethics Committee of the Centre intégré universitaire de santé et de services sociaux du Centre-Ouest-de-l'Île-de-Montréal.

## ***Measures***

### ***Sociodemographic and Medical Characteristics***

Medical data were provided by SPIN physicians upon enrollment in the SPIN Cohort, and included time since first non-Raynaud's phenomenon symptoms, time since SSc diagnosis, SSc subtype, degree of joint contractures for small and large joints, tendon friction rubs status, interstitial lung disease status, pulmonary arterial hypertension status, Raynaud's phenomenon status, digital ulcer status (digital pulp and anywhere else on the finger), and gastrointestinal tract involvement status (esophageal, stomach, and intestinal). For each participant, we calculated the

time from when sociodemographic and medical characteristics were obtained at entry into the SPIN Cohort to survey completion.

### *Physical Activity*

The SPIN Cohort assessment includes an item, “Compared to other people your age, how would you rate your physical activity during the past year” (physically inactive; somewhat active; moderately active; quite active; very active), followed by the item, “Do you exercise at present?” (yes; no). Among participants who reported exercising at present, 2 additional items were administered, “On the average, how many hours per week do you exercise” and “What type(s) of exercise(s) do you do?” [walking; jogging; aerobics; swimming; other (specify)]. For the “other” option, participants could indicate more than 1 type of exercise. All exercises described by participants in the “other” option were classified based on the 2011 Compendium of Physical Activities (16).

### *Physical Function*

We used the 4-item PROMIS Physical Function 4a v2.0 to evaluate self-reported physical activity capability. Each item is scored on a 5-point scale (1-5), where higher scores reflect better physical function over the previous 7 days. The total score is obtained by converting the sum of raw item scores into T-scores standardized from the general United States population [mean = 50, SD = 10]. The PROMIS Physical Function 4a v2.0 has been validated in SSc (17-19).

### *Functional Disability*

The Disability Index of the Health Assessment Questionnaire (HAQ-DI) assesses 8 disability categories over the past 7 days. Each item is rated on a 4-point scale, ranging from 0 (without any difficulty) to 3 (unable to do), where higher scores reflect greater functional

disability. The highest score from each category determines the score for that category, and the total score is the mean of the 8 category scores, ranging from 0 (no disability) to 3 (severe disability). The HAQ-DI is a valid measure of functional disability in SSc (20).

#### *SPIN Physical Activity Survey*

We developed the SPIN Physical Activity Survey (see Supplemental Appendix A) to evaluate whether possible physical activity barriers are experienced and, if so, their importance, and to evaluate possible facilitators for likelihood of use. An initial list of barriers and facilitators was generated via 9 nominal group technique interview sessions with 41 people with SSc at patient conferences in Canada, the United States, and France (13). Study investigators consolidated overlapping items, reworded unclear items, and excluded vague or unrelated items. Next, the 9-member SPIN Physical Activity Patient Advisory Team and SPIN-affiliated health care providers made recommendations to reword, exclude, or add barrier and facilitator items. The item list included 20 barriers classified into 4 categories (21); 14 were health and medical barriers; 4 social and personal; 1 time, work, and lifestyle; and 1 environmental. There were 91 barrier-specific facilitators and 12 general facilitators. Patient advisors pilot tested the survey and provided feedback on usability; survey instructions were revised accordingly. The survey was then translated into French using a standard forward–backward translation process (22).

In the survey, to reduce burden, participants were asked to select up to 10 of the 20 total barriers that they have experienced and believe are important for them, to initially order selected barriers from most to least important by dragging them into position, and to rate each selected barrier on a 4-point Likert scale based on importance to them when thinking about or actually being physically active (not important; somewhat important; important; very important). We next presented participants with all barrier-specific facilitators that corresponded to their selected

barriers, and they rated the likelihood that they would use each barrier-specific facilitator to overcome the corresponding barrier (not likely; somewhat likely; likely; very likely) and indicated whether they had previously tried it. Participants similarly rated general facilitators. At the end of the survey, participants could provide suggestions for additional barriers and facilitators.

### ***Data Analysis***

We used descriptive statistics. We summarized continuous variables using medians (ranges) and categorical variables using percentages and listed additional barriers and facilitators provided by participants. To gain further insights, we stratified the analyses related to barriers by whether participants exercised or not, as well as sex. In addition, because we believe that those who tried a facilitator that helped their physical activity would be likely to use it again, we stratified the analyses based on the likelihood of using facilitators separately by those who experienced the barrier and previously tried the facilitator in comparison to those who experienced the barrier but had not tried the facilitator.

We classified barriers using the same 4 categories used to classify them in the NGT study where the list was generated (13). Also, based on consensus among investigators and the SPIN Physical Activity Patient Advisory Team, we applied descriptive labels in the text to similar barriers and facilitators in order to clearly and succinctly summarize results. All analyses were conducted with Microsoft Excel version 16.16.

## **Results**

### ***Participant Characteristics***

Of 1,707 invited SPIN Cohort participants, 721 (42%) completed the full SPIN Physical Activity survey and were included in analyses; 70 who partially completed the survey were

excluded. The median (range) age was 59 (22 – 89), almost 90% were women, and almost half were employed full- or part-time (see Table 1). Median time since SSc diagnosis was 10.4 years, and approximately 40% had diffuse SSc. Approximately a third of participants were at least one standard deviation below the United States population mean on the PROMIS Physical Function 4a v2.0, and half had at least mild functional impairment (median HAQ-DI score = 0.6). As shown in Table 2, walking was performed by 47% of participants, and conditioning exercises by 26%.

As shown in Table 1, sociodemographic and medical characteristics of respondents were similar to non-respondents; the range of differences for categorical variables was 0% to 7%. However, there were some differences in physical activity characteristics between respondents and non-respondents. There was a 15% difference in the proportion who reported currently exercising (61% of respondents versus 46% of non-respondents), as well as differences in the proportion who performed specific types of exercises.

### ***Physical Activity Barriers***

There were 172 (24%) participants who experienced and selected 10 barriers for rating and 549 (76%) who selected fewer than 10; the median number of barriers selected was 7. As shown in Figure 1, there were 4 barriers, all health and medical barriers, that were experienced and selected for rating by  $\geq 50\%$  of 721 total participants, including Raynaud's phenomenon, fatigue, joint stiffness and contractures, and difficulty grasping objects. Of these, fatigue (58%) and Raynaud's phenomenon (57%) were selected for rating and classified as 'important' or 'very important' by  $\geq 50\%$  of total participants. Joint stiffness and contractures was selected and rated as 'important' or 'very important' by 49%, shortness of breath by 38%, gastrointestinal problems by 36%, both difficulty grasping objects and pain by 33%, muscle weakness and difficulty with



mobility by 29%, and lack of motivation and difficulty committing to exercise by 26%. See Supplemental Appendix B for summary of initial sorted rankings of barriers, rather than ratings, of importance.

Supplemental Appendices C and D illustrate the distribution of barrier ratings separately for participants who did (N = 433) and did not (N = 282) report presently engaging in exercise, respectively. Importance of barriers tended to be rated higher by those who did not exercise; the 3 largest differences in the percent rating barriers as ‘important’ or ‘very important’ were for lack of motivation (21% difference), fatigue (14% difference), and difficulty grasping objects (11% difference).

Supplemental Appendices E and F illustrate the distribution of barrier ratings for males (N = 81) and females (N = 640), respectively. Overall, the distributions of barrier ratings for males and females were generally similar; the two barriers with the largest differences were gastrointestinal problems (12%) and Raynaud’s (10%), which both had a higher percentage of females rating the barrier as ‘important’ or ‘very important’.

*[Insert figure 1 here]*

### ***Physical Activity Facilitators***

Overall, of 103 facilitators rated by participants who had experienced the linked barrier, 23 (22%) were rated as ‘likely’ or ‘very likely’ to use by  $\geq 75\%$  of participants and an additional 58 (56%) facilitators were by  $\geq 50\%$ . The full list of barriers, their facilitators, and participant ratings is available in Supplemental Appendix G. It is also accessible online as an interactive spreadsheet (<https://osf.io/2mxj5/>) that facilitates sorting and identifying facilitators for different barriers. Table 3 presents the 12 health and medical barriers that were experienced and selected for rating by  $\geq 25\%$  of total participants and a selection of corresponding barrier-specific

facilitators that were commonly rated as ‘likely’ or ‘very likely’ to use among those who tried them. The most common facilitators overall and among those presented in Table 3 involved strategies for adapting exercise type, conduct or setting (e.g., using controlled, slow movement); changing health behaviours to take care of the body (e.g., stretching); keeping warm (e.g., wearing gloves); and protecting the skin (e.g., covering ulcers). Supplemental Appendix H presents additional barrier and facilitator suggestions to those presented in our survey that were provided by survey respondents and were substantively different from those included in the survey.

The majority (62/103; 60%) of facilitators had been tried by  $\geq 50\%$  of participants who rated them. Among those who tried facilitators, 103/103 facilitators were rated by  $\geq 50\%$  as ‘likely’ or ‘very likely’ to use and 65/103 facilitators were rated by  $\geq 80\%$  as ‘likely’ or ‘very likely’ to use. In contrast, only 12/103 facilitators were rated as ‘likely’ or ‘very likely’ to use by  $\geq 50\%$  of participants who had not tried them previously.

## Discussion

The main results of our study include prevalence of barriers to physical activity among over 700 people with SSc, along with their ratings of the importance of each barrier and of the likelihood that they would use corresponding and more general facilitators of physical activity. The most common barriers to physical activity were Raynaud’s phenomenon and fatigue, followed by compromised hand dexterity and challenges related to respiratory, gastrointestinal and skin pathologies. Among the 103 barrier-specific and general facilitators in the survey, for participants who had tried each of them, at least 50% of participants said they would be ‘likely’ or ‘very likely’ to use them to facilitate physical activity. Health care providers can use our interactive Excel spreadsheet (<https://osf.io/2mxj5/>) to review physical activity barriers and

identify patient-generated facilitators to address them and support physical activity among individuals with SSc.

Although this was the first study to evaluate patient-generated physical activity barriers and possible facilitators to overcome them in a large SSc sample, results are consistent with findings from previous studies. A previous study with the SPIN Cohort ( $n = 752$ ) found that presently reported exercise was associated with fatigue, pain, degree of skin thickening, and functional disability (9), all of which were identified by participants in the present study as barriers. Facilitators rated widely as likely to be used for such barriers were often related to adapting the exercise form (e.g., use controlled, slow movements for pain), conduct (e.g., take rest breaks for fatigue, pain, and muscle weakness and difficulty with mobility), and equipment (e.g., use wrist weights for difficulty grasping objects). Consistent with the shortness of breath barrier, lung involvement (23) and pulmonary hypertension (24) have been found to be associated with reduced aerobic capacity in 2 small exercise studies ( $n = 46$  and 18 SSc patients). Two of our barrier-specific facilitators ('take rest breaks while exercising' and 'lower the intensity of exercise to not experience shortness of breath') directly address reduced aerobic capacity.

Barriers outside the medical category were generally less common than medical barriers. The most common was 'lack of motivation', which was rated 'important' or 'very important' by 26% of total participants, followed by 'finding time available to schedule exercise' (16%) and 'feeling embarrassed or discouraged due to physical ability, appearance, or judgement from others' (12%). While motivation- and time-related barriers have been reported as important barriers to physical activity in the general population (25, 26), the barrier about feeling embarrassed or discouraged seems to more directly reflect the unique experiences of people with

SSc, particularly psychosocial consequences due to concerns about visible changes to one's appearance (27).

Sub-group analyses revealed that a substantially larger proportion of inactive than active participants had rated 2 health and medical barriers (fatigue, difficulty grasping objects) and 1 social and personal barrier (lack of motivation) as 'important' or 'very important'. These 3 barriers could be targeted when developing general interventions to promote physical activity in SSc patients.

All facilitators were rated by at least half of participants who tried them as 'likely' or 'very likely' to use. Some facilitators commonly rated as likely to be used are consistent with widely recommended strategies, such as for warming in Raynaud's phenomenon (28), and identifying enjoyable activities for people who have difficulty with motivation or exercise adherence (29). On the other hand, there were novel barrier-specific facilitators widely perceived as likely to be used that, to our knowledge, have not been reported in the literature but could be helpful for health care providers promoting physical activity to individuals with SSc. Many novel facilitators addressed adapting the exercise, either by adapting the exercise conduct, type, or setting, including 'use adapted exercise equipment' (barriers of difficulty grasping objects and joint stiffness and contractures), and 'participate in gentle exercise classes that may be intended for new exercisers or people with limitations for exercising' (barrier of fear of injury or extended recovery time). Importantly, individuals with SSc should consult a qualified clinician about how to exercise safely.

In general, participants who tried facilitators rated them favourably as 'likely' or 'very likely' to use in comparison to those who had not tried them. This suggests some challenges may exist when proposing new facilitators to SSc patients. Communication skills and strategy may be

very important. A widely used intervention to support physical activity in the general population, Active Living Every Day (ALED) (30), uses a social modelling component when exposing individuals to new facilitators. This involves sharing the personal experiences of people who describe how they overcame specific barriers to leading a more active lifestyle. We expect that such social modelling would be a potentially effective strategy to promote physical activity in SSc, especially for those patients who had not tried a proposed facilitator.

Our findings suggest barriers that could be targeted to facilitate physical activity. Strategies to treat fatigue in rheumatoid arthritis include exercise, cognitive behavioural therapy, and self-management programs (31); SPIN is currently testing a SSc self-management program (SPIN-SELF) (32). Strategies to reduce the effects of Raynaud's include keeping a diary and identifying activities that trigger attacks; keeping the body and hands warm (e.g., layered clothing, gloves); and avoiding smoking (33). Limitations in mobility, which are common in the hands (34), may be addressed through hand stretches and exercises, and SPIN has developed the SPIN-HAND Program, which is available online, free-of-charge (35). Social support is a strong predictor of exercise intention and stage of behaviour change for exercise (36). Many people with SSc attend support groups (37), and the SPIN-SELF Program also contains a group component.

There are limitations to take into account in interpreting results of the present study. First, the results may not be generalizable to people who do not speak English or French, reside outside of North America and Europe, or do not have access to a device with Internet. Second, a higher proportion of respondents (61%) reported currently exercising in comparison to SPIN Cohort non-respondents (46%). Third, participants were presented with 20 possible barriers, but in order to reduce respondent burden, we only allowed them to select up to 10 barriers which

they had experienced. Almost 25% of participants selected 10 barriers and might have experienced and selected additional barriers, if that had been permitted, although these would have been of lesser importance to the participant than the ones they selected. Fourth, although participants were asked to select the barriers for rating that they experienced and feel are important, some participants rated at least one of their selections as ‘not important’. Fifth, although participants rated the importance of barriers and likelihood of using facilitators, the survey did not elicit explanations for why they rated barriers and facilitators as they did. Such explanations might help to fine-tune guidance to better address physical activity difficulties experienced by individuals with SSc. Sixth, although our measure of physical activity behaviour was modelled after part of an existing validated questionnaire (38, 39), we did not administer a validated measure of physical activity behaviour, which would have allowed us to better characterize participants and to compare their physical activity behaviour with other samples. This was an effort to reduce respondent burden because there were constraints on the number of items that we were able to add to a pre-existing cohort assessment. One area of future research could include comparing general levels of physical activity behaviour in SSc patients to the published norms in the general population.

In summary, medical-related barriers to activity were most commonly experienced and considered important; Raynaud’s phenomenon and fatigue were the most commonly experienced. Facilitators widely considered likely to be used addressed adapting exercise type or setting, using health behaviours to take care of the body, and using clothing or materials to protect the skin or to keep warm. Participants who had tried facilitators were generally more likely to use them again compared to participants who had never tried them. Our online interactive Excel file (<https://osf.io/2mxj5/>) allows health care providers to easily identify

475 relevant facilitators for common barriers to physical activity experienced by individuals with  
476 SSc.

477

**References**

1. Seibold JR. Scleroderma. In: Harris E, editor. Kelley's textbooks of rheumatology. 7th ed. Philadelphia: Elsevier; 2005. p. 1279-80.
2. Wigley FM. Clinical features of systemic sclerosis. In: Hochberg MC, editor. Rheumatology. 3rd ed. Philadelphia: Mosby; 2003. p. 1463-364.
3. Hudson M, Thombs BD, Steele R, Panopalis P, Newton E, Baron M, et al. Health-related quality of life in systemic sclerosis: a systematic review. *Arthritis Care Res* 2009; 61: 1112-20.
4. Mayes MD. Systemic sclerosis: clinical features. In: Klippel JH, Stone JH, White PH, editors. *Primer on the Rheumatic Diseases*. New York: Springer Science & Business Media; 2008. p. 343-50.
5. Gelber AC, Manno RL, Shah AA, Woods A, Le EN, Boin F, et al. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. *Medicine* 2013; 92: 191-205.
6. Reiner M, Niermann C, Jekauc D, Woll A. Long-term health benefits of physical activity—a systematic review of longitudinal studies. *BMC Public Health* 2013; 13: 813.
7. Warburton DE, Charlesworth S, Ivey A, Nettlefold L, Bredin SS. A systematic review of the evidence for Canada's physical activity guidelines for adults. *Int J Behav Nutr Phys Act* 2010; 7: 39.



- 496 8. Perandini LA, de Sá-Pinto AL, Roschel H, Benatti FB, Lima FR, Bonfá E, et al. Exercise as a  
497 therapeutic tool to counteract inflammation and clinical symptoms in autoimmune rheumatic  
498 diseases. *Autoimmun Rev* 2012; 12: 218-24.
- 499 9. Azar M, Rice DB, Kwakkenbos L, Carrier M, Shrier I, Bartlett SJ, et al. Exercise habits and  
500 factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered  
501 Intervention Network (SPIN) cohort study. *Disabil Rehabil* 2018; 40: 1997-2003.
- 502 10. Battaglia S, Bellia M, Serafino-Agrusa L, Giardina A, Messina M, Cannizzaro F, et al.  
503 Physical capacity in performing daily activities is reduced in scleroderma patients with early  
504 lung involvement. *Clin Respir J* 2017; 11: 36-42.
- 505 11. Pettersson H, Åkerström A, Nordin A, Svenungsson E, Alexanderson H, Boström C. Self-  
506 reported physical capacity and activity in patients with systemic sclerosis and matched controls.  
507 *Scand J Rheumatol* 2017; 46: 490-5.
- 508 12. Liem S, Meessen J, Wolterbeek R, Marsan NA, Ninaber M, Vlieland TV, et al. Physical  
509 activity in patients with systemic sclerosis. *Rheumatol Int.* 2018; 38: 443-53.
- 510 13. Harb S, Cumin J, Rice DB, Peláez S, Hudson M, Bartlett SJ, et al. Identifying barriers and  
511 facilitators to physical activity for people with scleroderma: a nominal group technique study.  
512 *Disabil Rehabil* 2020: 1-8.
- 513 14. Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013  
514 classification criteria for systemic sclerosis: an American College of Rheumatology/European  
515 League against Rheumatism collaborative initiative. *Arthritis Rheum* 2013; 65: 2737-47.

- 516 15. Qualtrics. Provo U. Qualtrics survey platform. 2002.
- 517 16. Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR, Tudor-Locke C, et al.  
518 2011 compendium of physical activities: a second update of codes and MET values. *Med Sci*  
519 *Sports Exerc* 2011; 43: 1575-81.
- 520 17. Kwakkenbos L, Thombs BD, Khanna D, Carrier M, Baron M, Furst DE, et al. Performance  
521 of the patient-reported outcomes measurement information system-29 in scleroderma: a  
522 Scleroderma Patient-centered Intervention Network Cohort study. *Rheumatology* 2017; 56:  
523 1302-11.
- 524 18. Hinchcliff M, Beaumont JL, Thavarajah K, Varga J, Chung A, Podluszky S, et al. Validity of  
525 two new patient-reported outcome measures in systemic sclerosis: Patient-reported outcomes  
526 measurement information system 29-item health profile and functional assessment of chronic  
527 illness therapy–dyspnea short form. *Arthritis Care Res* 2011; 63: 1620-8.
- 528 19. Hinchcliff ME, Beaumont JL, Carns MA, Podluszky S, Thavarajah K, Varga J, et al.  
529 Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosis. *J*  
530 *Rheumatol* 2015; 42: 64-72.
- 531 20. Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. Correlates of the  
532 disability index of the health assessment questionnaire: a measure of functional impairment in  
533 systemic sclerosis. *Arthritis Rheum* 1999; 42: 2372-80.

- 534 21. Lascar N, Kennedy A, Hancock B, Jenkins D, Andrews RC, Greenfield S, et al. Attitudes and  
535 barriers to exercise in adults with type 1 diabetes (T1DM) and how best to address them: a  
536 qualitative study. PLoS One 2014; 9: e108019.
- 537 22. Process of translation and adaptation of instruments [homepage on the Internet]. [cited 05/08  
538 2020]. Available from: [https://www.who.int/substance\\_abuse/research\\_tools/translation/en/](https://www.who.int/substance_abuse/research_tools/translation/en/).
- 539 23. Cuomo G, Santoriello C, Polverino F, Ruocco L, Valentini G, Polverino M. Impaired  
540 exercise performance in systemic sclerosis and its clinical correlations. Scand J Rheumatol 2010;  
541 39: 330-5.
- 542 24. Morelli S, Ferrante L, Sgreccia A, Eleuteri ML, Perrone C, De Marzio P, et al. Pulmonary  
543 hypertension is associated with impaired exercise performance in patients with systemic  
544 sclerosis. Scand J Rheumatol 2000; 29: 236-42.
- 545 25. Salmon J, Owen N, Crawford D, Bauman A, Sallis JF. Physical activity and sedentary  
546 behavior: a population-based study of barriers, enjoyment, and preference. Health Psychol 2003;  
547 22: 178.
- 548 26. Booth ML, Bauman A, Owen N, Gore CJ. Physical activity preferences, preferred sources of  
549 assistance, and perceived barriers to increased activity among physically inactive Australians.  
550 Prev Med 1997; 26: 131-7.
- 551 27. Jewett LR, Hudson M, Malcarne VL, Baron M, Thombs BD, Canadian Scleroderma  
552 Research Group. Sociodemographic and disease correlates of body image distress among  
553 patients with systemic sclerosis. PloS One 2012; 7: e33281.

- 554 28. Wigley FM, Flavahan NA. Raynaud's phenomenon. *N Engl J Med* 2016; 375: 556-65.
- 555 29. Richard M, Christina MF, Deborah LS, Rubio N, Kennon MS. Intrinsic motivation and  
556 exercise adherence. *Int J Sport Psychol* 1997; 28: 335-54.
- 557 30. Blair SN, Dunn AL, Marcus BH, Carpenter RA, Jaret P. *Active living every day*. Human  
558 Kinetics; 2010.
- 559 31. Pope JE. Management of fatigue in rheumatoid arthritis. *RMD Open* 2020; 6: e001084.
- 560 32. Carrier ME, Kwakkenbos L, Nielson WR, Fedoruk C, Nielsen K, Milette K, et al. The  
561 Scleroderma Patient-centered Intervention Network Self-Management Program: Protocol for a  
562 Randomized Feasibility Trial. *JMIR Res Protoc* 2020; 9: e16799.
- 563 33. Kwakkenbos L, Thombs BD. Non-drug approaches to treating Raynaud's phenomenon. In:  
564 Raynaud's Phenomenon. New York: Springer; 2015. p. 299-313.
- 565 34. Bassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact  
566 of symptoms experienced by patients with systemic sclerosis: results from a Canadian National  
567 Survey. *Rheumatology* 2011; 50: 762-7.
- 568 35. Kwakkenbos L, Carrier ME, Boutron I, Welling J, Sauvé M, van den Ende CH, et al.  
569 Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Hand  
570 Exercise Program (SPIN-HAND). *J Rheumatol* 2019; 46: 816.
- 571 36. Courneya KS, Plotnikoff RC, Hotz SB, Birkett NJ. Social support and the theory of planned  
572 behavior in the exercise domain. *Am J Health Behav* 2000; 24: 300-8.

- 573 37. Gumuchian ST, Delisle VC, Kwakkenbos L, Pépin M, Carrier ME, Malcarne VL, et al.  
574 Reasons for attending support groups and organizational preferences: the European scleroderma  
575 support group members survey. *Disabil Rehabil* 2019; 41: 974-82.
- 576 38. Godin G. The Godin-Shephard leisure-time physical activity questionnaire. *HFJC* 2011; 4:  
577 18-22.
- 578 39. Amireault S, Godin G. The Godin-Shephard leisure-time physical activity questionnaire:  
579 validity evidence supporting its use for classifying healthy adults into active and insufficiently  
580 active categories. *Percept Mot Skills* 2015; 120: 604-22.
- 581

**Table 1. Participant sociodemographic and medical characteristics.** Percentages refer to the percent of data recorded.

Variable	SPIN Cohort respondents (N = 721)	SPIN Cohort non- respondents (N = 986)
Sociodemographic variables		
Age in years, <i>median (range)</i>	59 (22 to 89)	57 (21 to 91)
Women, <i>n (%)</i>	640 (89%)	865 (88%)
White race/ethnicity, <i>n (%)</i>	603 (85%) <sup>a</sup>	717 (79%) <sup>b</sup>
Years of education completed, <sup>c</sup> <i>median (range)</i>	16 (3 to 27) <sup>d</sup>	15 (0 to 28) <sup>e</sup>
Employed full- or part-time, <i>n (%)</i>	323 (46%) <sup>d</sup>	369 (41%) <sup>f</sup>
Married or living as married, <i>n (%)</i>	455 (64%) <sup>d</sup>	547 (61%) <sup>f</sup>
Geographic region, <i>n (%)</i>		
North America	429 (60%)	584 (59%)
Europe	292 (40%)	401 (41%)
Australia	0 (0%)	1 (0%)
English survey language, <i>n (%)</i>	447 (62%)	649 (69%) <sup>g</sup>
Medical variables		
Time in years since baseline assessment when medical data were recorded, <i>median (range)</i>	3.1 (0.4 to 5.8)	3.1 (0.4 to 6.7)
Time in years since first non-Raynaud's phenomenon symptom, <i>median (range)</i>	12.3 (0.4 to 47.3) <sup>h</sup>	11.3 (1.6 to 58.8) <sup>i</sup>

Time in years since systemic sclerosis diagnosis, <i>median (range)</i>	10.4 (0.4 to 43.8) <sup>j</sup>	9.8 (0.8 to 58.8) <sup>k</sup>
Diffuse systemic sclerosis subtype, <i>n (%)</i>	279 (39%) <sup>l</sup>	409 (42%) <sup>m</sup>
Body mass index, <i>median (range)</i>	24.0 (14.7 to 60.7)	24.6 (13.0 to 64.4)
Raynaud's phenomenon, <i>n (%)</i>	695 (98%) <sup>n</sup>	963 (98%) <sup>m</sup>
Digital ulcers (distal pulp), <i>n (%)</i>	238 (34%) <sup>o</sup>	364 (38%) <sup>p</sup>
Digital ulcers (anywhere else on the finger), <i>n (%)</i>	101 (15%) <sup>q</sup>	184 (19%) <sup>r</sup>
Current or past tendon friction rubs, <i>n (%)</i>	154 (25%) <sup>s</sup>	210 (24%) <sup>t</sup>
Moderate or severe contractures of small joints, <i>n (%)</i>	172 (26%) <sup>u</sup>	253 (27%) <sup>v</sup>
Moderate or severe contractures of large joints, <i>n (%)</i>	79 (12%) <sup>w</sup>	136 (15%) <sup>x</sup>
Any gastrointestinal involvement, <i>n (%)</i>	621 (87%) <sup>y</sup>	873 (89%) <sup>z</sup>
Interstitial lung disease, <i>n (%)</i>	228 (33%) <sup>aa</sup>	346 (36%) <sup>ab</sup>
Pulmonary arterial hypertension, <i>n (%)</i>	45 (7%) <sup>ac</sup>	80 (9%) <sup>ad</sup>
Physical function domain score of the Patient Reported Outcomes Measurement Information System (PROMIS-29) profile version 2.0, <i>median (range)</i>	43.4 (22.9 to 56.9) <sup>ae</sup>	41.8 (22.9 to 56.9) <sup>af</sup>
Total score of the Disability Index of the Health Assessment Questionnaire (HAQ-DI), <i>median (range)</i>	0.6 (0.0 to 3.0) <sup>ag</sup>	0.6 (0.0 to 3.0) <sup>ah</sup>

Due to missing data: <sup>a</sup> N = 714; <sup>b</sup> N = 912; <sup>d</sup> N = 708; <sup>e</sup> N = 900; <sup>f</sup> N = 903; <sup>g</sup> N = 935; <sup>h</sup> N = 666; <sup>i</sup> N = 899; <sup>j</sup> N = 697; <sup>k</sup> N = 939; <sup>l</sup> N = 713; <sup>m</sup> N = 979; <sup>n</sup> N = 711; <sup>o</sup> N = 703; <sup>p</sup> N = 970; <sup>q</sup> N = 692; <sup>r</sup> N = 944; <sup>s</sup> N = 618; <sup>t</sup> N = 865; <sup>u</sup> N = 673; <sup>v</sup> N = 934; <sup>w</sup> N = 657; <sup>x</sup> N = 918; <sup>y</sup> N = 706; <sup>z</sup> N = 983; <sup>aa</sup> N = 692; <sup>ab</sup> N = 974; <sup>ac</sup> N = 691; <sup>ad</sup> N = 937; <sup>ae</sup> N = 705; <sup>af</sup> N = 876; <sup>ag</sup> N = 701; <sup>ah</sup> N = 862.

<sup>c</sup> Years of education completed beginning from elementary/primary school and including all levels of formal education.

**Table 2. Participant physical activity characteristics.** Percentages refer to the percent of data recorded.

Variable	SPIN Cohort respondents (N = 715 due to missing values)	SPIN Cohort non-respondents (N = 933)
Participants' perception of their physical activity level in the past year compared to other people their age, <i>n (%)</i>		
Physically inactive	85 (12%)	155 (17%) <sup>a</sup>
Somewhat active	199 (28%)	316 (34%) <sup>a</sup>
Moderately active	233 (33%)	270 (29%) <sup>a</sup>
Quite active	148 (21%)	115 (12%) <sup>a</sup>
Very active	50 (7%)	66 (7%) <sup>a</sup>
Currently exercise, <i>n (%)</i>	433 (61%)	421 (46%) <sup>b</sup>
Average hours per week of exercise (among participants who currently exercise), <i>median (range)</i>	4 (1 to 15) <sup>c</sup>	4 (1 to 15) <sup>d</sup>
Types of exercises performed, <i>n (%)</i>		
Walking	333 (47%)	328 (35%)
Jogging	24 (3%)	25 (3%)
Aerobics	75 (11%)	64 (7%)
Swimming	59 (8%)	41 (4%)
Other	275 (39%)	209 (22%)



Categories of “other” exercises (selected participant examples in parentheses),<sup>e</sup> *n* (%)

Bicycling (biking, cycling, spinning)	42 (6%)	29 (3%)
Conditioning (elliptical, gym, Pilates, stretching, tai chi, weight lifting, yoga)	183 (26%)	152 (16%)
Lawn and garden (gardening, landscaping, yard work)	16 (2%)	9 (1%)
Sports (badminton, racquetball, bowling, golf)	25 (4%)	26 (3%)
Walking (Nordic walking)	13 (2%)	9 (1%)
Water activities (aquatic classes, kayaking, pool exercises)	14 (2%)	7 (1%)
Other categories <sup>f</sup>	52 (7%)	12 (1%)

---

Due to missing data: <sup>a</sup> N = 922; <sup>b</sup> N = 921.

<sup>c</sup> N = 433 who reported currently exercising and their average hours per week of exercise.

<sup>d</sup> N = 418 who reported currently exercising and their average hours per week of exercise.

<sup>e</sup> Participants could indicate > 1 exercise and each exercise was classified into one category.

<sup>f</sup> Other categories of activities performed by ≤ 2% of participants were dancing, fishing and hunting, home activity, miscellaneous, music playing, and winter activities.

**Table 3. The 12 medical barriers experienced and selected for rating by  $\geq 25\%$  of participants, and a subset of corresponding novel and common facilitators (n = 721 total participants). See interactive Excel file (<https://osf.io/2mxj5/>) for the full list.**

Barrier and (%) N who experienced and selected for rating	Facilitators	Tried facilitator and ‘likely’ or ‘very likely’ to use it, <sup>a</sup> % (N)
<b>Raynaud’s phenomenon</b> 78% (564)	<ul style="list-style-type: none"> <li>• Dress to stay warm (keep your core warm and cover areas of the body that become cold – e.g., wear a warm hat, gloves, or mittens)</li> <li>• Exercise in an area with a temperature that is comfortable for you</li> <li>• Wear heated or non-heated warm gloves or mittens and socks</li> <li>• Insert warmers (i.e., liners, or electric or chemical warmers) in gloves or mittens or socks</li> </ul>	93% (501 of 539)
		90% (451 of 502)
		92% (452 of 494)
		86% (334 of 387)
<b>Fatigue</b>	<ul style="list-style-type: none"> <li>• Take rest breaks while exercising (e.g., between activities)</li> </ul>	83% (333 of 403)

71% (508)

- Break exercise into several short periods (e.g., three 10-minute walks) rather than a single long period (e.g., one 30-minute walk) 82% (235 of 286)

- Get enough sleep and plan to take a nap during the day 80% (273 of 342)

**Joint stiffness and contractures**

60% (434)

- Do daily gentle stretching and exercises that move your joints through their maximum range of motion 82% (256 of 312)

- Use controlled, slow movements that are comfortable for you 85% (263 of 309)

**Difficulty grasping objects**

51% (365)

- Use adapted exercise equipment (e.g., weights with a larger handle, or wrist weights) 82% (108 of 132)

**Shortness of breath**

47% (338)

- Lower the intensity of the exercise to not experience shortness of breath 86% (251 of 291)

**Gastrointestinal problems**

46% (334)

- If you have acid reflux, modify exercise positions to keep your body upright (e.g., do push-ups against the 89% (148 of 166)

	wall instead of push-ups against the ground)	
<b>Pain</b> 42% (300)	<ul style="list-style-type: none"> <li>• Modify exercise so it does not cause pain (e.g., use lighter weights or walk slower)</li> </ul>	87% (223 of 256)
<b>Itching or dryness of skin</b> 40% (289)	<ul style="list-style-type: none"> <li>• Moisturize regularly or as needed (e.g., use lotion, or wear moisturizing gloves or socks)</li> </ul>	89% (223 of 251)
<b>Muscle weakness and difficulty with mobility</b> 36% (258)	<ul style="list-style-type: none"> <li>• If you have difficulty with balance, place a hand against an immovable object (e.g., wall or pole) for support, or exercise while sitting on an immovable chair or seat</li> <li>• If you have difficulty with balance, use assistive devices (e.g., hiking poles)</li> </ul>	88% (151 of 172)  81% (77 of 95)
<b>Difficulty with bowel and bladder control</b> 28% (205)	<ul style="list-style-type: none"> <li>• Wear a pad or underwear designed for bowel and bladder control issues</li> </ul>	90% (132 of 146)
<b>Ulcers or sores on hands or feet</b> 27% (195)	<ul style="list-style-type: none"> <li>• Apply non-adhesive bandages to cover and protect ulcers or sores</li> </ul>	92% (140 of 153)

	<ul style="list-style-type: none"> <li>• Wear appropriate clothing to cover and protect ulcers or sores (e.g., gloves or mittens)</li> </ul>	90% (148 of 165)
	<ul style="list-style-type: none"> <li>• If you have foot ulcers or sores, put pads in shoes or wear specialized soles or shoes (e.g., open toe shoes)</li> </ul>	87% (65 of 75)
<b>Activities involving water may worsen condition of hands or skin on other areas of the body</b>	<ul style="list-style-type: none"> <li>• Wear a wet suit, gloves, or socks designed for water exercises to stay warm</li> </ul>	72% (33 of 46)
		26% (188)

---

<sup>a</sup> We present the percentage and number of participants who rated the facilitator as ‘likely’ or ‘very likely’ to use among those who experienced the barrier and had tried the facilitator. Participants rated on a 4-point Likert scale the likelihood that they would use each barrier-specific facilitator to overcome the corresponding barrier to be physically active (not likely; somewhat likely; likely; very likely).

585 **Figure 1. Distribution of ratings for barriers (n = 721 total participants).** Participants only  
586 rated up to a maximum of 10 barriers which they experienced and selected for rating. Using a 4-  
587 point Likert scale, they rated each of their selected barriers based on how important it is to them  
588 personally when thinking about or actually being physically active (not important; somewhat  
589 important; important; very important). Because 172 participants rated the maximum of 10  
590 barriers, it is possible that they experienced other barriers as well. Percentages refer to the  
591 percent of 721 participants who rated the adjacent barrier as ‘important’ or ‘very important’.